HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife

This article was originally published in The Rose Sheet

Executive Summary

Russian market uncertainty "appears to be particularly challenging" and is expected to cause Herbalife's sales in the country to "decline substantially" in the second half of 1998, the direct marketer stated Sept. 1. Retail sales in Russia accounted for 7.8%, or $30.9 mil., of the firm's total sales for the second quarter ("The Rose Sheet" June 27, In Brief). Financial analysts Soloman Smith Barney estimated Herbalife could expect a 35% sales decline in Russia in the second half. Herbalife will take a $5 mil. non-recurring charge in the third quarter to increase "its accounting reserves against inventory and accounts receivable in anticipation of a sales decline and currency restrictions," the firm said. Despite the anticipated results, Herbalife said Russia remains an "attractive market over the long term"...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel